High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial

Yoshioka, Yasuo; Nose, Takayuki; Yoshida, Ken; Inoue, Takehiro; Yamazaki, Hideya; Tanaka, Eiichi; Shiomi, Hiroya; Imai, Atsushi; Nakamura, Satoaki; Shimamoto, Shigetoshi; Inoue, Toshihiko

doi:10.1016/s0360-3016(00)00687-8

Cited by 140 publications

(89 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median of flow rate test pretreatment in our study was 12.5 ml/s (3-30 ml/s) but acute urinary retention was seen in only 1 patient, requiring a temporary postimplant bladder catheter during seven days, this results are better than other investigators [13][14][15][16].…”

Section: Resultscontrasting

confidence: 42%

High-Dose-Rate Interstitial Brachytherapy as Monotherapy in One Fraction for the Treatment of Favorable Stage Prostate Cancer

Prada¹

2013

Advances in Prostate Cancer

View full text Add to dashboard Cite

Section: Resultscontrasting

confidence: 42%

High-Dose-Rate Interstitial Brachytherapy as Monotherapy in One Fraction for the Treatment of Favorable Stage Prostate Cancer

Prada¹

2013

Advances in Prostate Cancer

View full text Add to dashboard Cite

“…These observations led to use of high dose rate brachytherapy (HDR), first as a boost [17][18][19], and then as definitive monotherapy [20][21][22][23]. Due to its superior conformality, HDR could deliver high bioequivalent doses while sparing neighboring critical structures.…”

Section: Introductionmentioning

confidence: 99%

Hypofractionated SBRT Versus Conventionally Fractionated EBRT for Prostate Cancer: Comparison of PSA Slope and Nadir

Anwar

Weinberg

Chang

et al. 2013

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Background: Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development, and long-term follow-up is not yet available. However, rapid post-treatment PSA decline and low PSA nadir have been linked to improved clinical outcomes. The purpose of this study was to compare the PSA kinetics between CF-EBRT and SBRT in newly diagnosed localized prostate cancer. Materials/methods: 75 patients with low to low-intermediate risk prostate cancer (T1-T2; GS 3 + 3, PSA < 20 or 3 + 4, PSA < 15) treated without hormones with CF-EBRT (>70.2 Gy, <76 Gy) to the prostate only, were identified from a prospectively collected cohort of patients treated at the University of California, San Francisco (1997. Patients were excluded if they failed therapy by the Phoenix definition or had less than 1 year of follow-up or <3 PSAs. 43 patients who were treated with SBRT to the prostate to 38 Gy in 4 daily fractions also met the same criteria. PSA nadir and rate of change in PSA over time (slope) were calculated from the completion of RT to 1, 2 and 3 years post-RT.

show abstract

“…The preliminary biochemical PSA control rate was 98% at 3 years and it was similar to their experience with standard 103 Pd low dose rate brachytherapy [40]. In a similar experience using HDR, Yashioka and colleagues from Japan used higher total doses up to 48-50 Gy in 6 Gy fractions as monotherapy for localized prostate cancer without untoward toxicity [33][34]. Considering all of these experiences as basis for dose selection, we will use a starting dose of 9 Gy per fraction and deliver a total of 5 fractions to a total dose of 45 Gy.…”

Section: 4mentioning

confidence: 49%

Development of a Phase I/II Clinical Trial Using Sterotactic Body Radiation Therapy (SBRT) for the Treatment of Localized Prostate Carcinoma

Timmerman¹

2006

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information ABSTRACT Background: Stereotactic body radiation therapy (SBRT) is a new therapeutic paradigm for treating localized tumors outside of the central nervous system and involves delivering very high doses of focused radiation using unique beam arrangements and special immobilization equipment. It has also been shown recently that many prostate cancers may be better controlled using large dose per fraction treatments such as might be delivered by SBRT. While large dose per fraction treatments are facilitated by new generation radiation delivery equipment, technology cannot independently overcome normal tissue consequences to tubular organs adjacent or within targets (e.g., the urethra and rectum for prostate cancer). As such, careful prospective clinical trials must be designed that appropriate bridge the information learned from laboratory testing, historical clinical experience, and the clinical experience with SBRT from other sites in order to test this new therapy for prostate cancer. Objective: Our goal is ultimately to carry out a prospective phase I/II trial of SBRT for treatment of localized prostate cancer such that its true efficacy and toxicity might be characterized. The objective of this application is to establish the collaborations necessary for formulating these protocols, write the protocols, assemble the clinical research infrastructure necessary for submitting the protocols, set up mechanisms for multi-center participation with our center acting as the coordinating center, recruiting, enrolling, treating and following patients, and to support the research infrastructure and clinical researchers performing these tasks Specific Aims: 1) Perform dosimetric evaluation of optimal beam geometry, beam shaping and intensity mapping in conjunction with physical maneuvers to avoid damaging dose to normal tissues. 2) Form relationships and agreements with important collaborators both at our institution and at a limited number of outside institutions that will facilitate the ultimate success of a clinical protocol. 3) Construct a protocol for testing very large dose per fraction radiation that properly selects patients, requires uniform SBRT treatment, and defines adequate follow-up toward measuring the defined endpoints. 4) Devise strategies for recruitment of the appropriate patient population for the protocol. 5) Develop a rudimentary information system capable of patient related data exchange between departments and institutions. Study Design: This development effort will employ a team appro...

show abstract

High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial

Abstract: Acute toxicity with this method was acceptable. Further patient accrual and longer follow-up will allow comparison to other techniques.

Cited by 140 publications

References 14 publications

High-Dose-Rate Interstitial Brachytherapy as Monotherapy in One Fraction for the Treatment of Favorable Stage Prostate Cancer

High-Dose-Rate Interstitial Brachytherapy as Monotherapy in One Fraction for the Treatment of Favorable Stage Prostate Cancer

Hypofractionated SBRT Versus Conventionally Fractionated EBRT for Prostate Cancer: Comparison of PSA Slope and Nadir

Development of a Phase I/II Clinical Trial Using Sterotactic Body Radiation Therapy (SBRT) for the Treatment of Localized Prostate Carcinoma

Contact Info

Product

Resources

About